Table 1. Input parameters and disease risk estimates following testing for all case study scenarios.

accuracy for genotyping C9orf72 STRE with repeat-primed polymerase chain reaction and amplicon-length analysis (45). "Risk following positive results in primary screening and confirmatory estimates in the ALS case study; \*includes FUS variants classified as pathogenic or likely pathogenic for ALS in the ClinVar database and recorded within ALS population databases (see Table S3, nucleotide variant; STRE = short tandem repeat expansion. §Estimates are based on populations of predominantly European ancestry – 95% confidence intervals shown for newly derived Parameter ascertainment is comprehensively described within Supplementary Materials 3. HD = Huntington's disease; ALS = amyotrophic lateral sclerosis; PKU = phenylketonuria. SNV = single tests relative to a negative screening result (probability of PKU given a negative metabolic screening result is approximated as 1×10-6). Probabilities are defined in the methods. Table S4); ¶defined by variant calling performance benchmarks of tools for genotyping in sequencing data by variant type (see Table S1) and, where marked †, by aggregate laboratory

00	<b>3</b> : <b>PKU</b> P <sub>/</sub> sc		<i>2: ALS</i>						1:		1	Case Ge study (
Coming committee only	PAH (positive metabolic	PAH (screening)	C9orf72 (positive sequencing screening confirmation)	C9orf72	FUS (ClinVar*)	FUS (all)	SOD1 (A5V)	SOD1 (all)	HTT (targeted)	HTT (screening)	1	Gene containing marker Variant (case study scenario) type
	VNS	VNS	STRE	STRE	VNS	VNS	VNS	VNS	STRE	STRE		Variant type
	0.167	0.000100	0.0052	0.00333	0.00333	0.00333	0.00333	0.00333	0.500	0.000410	P(D)	Pre-test disease probability <sup>§</sup>
	0.743	0.743	0.0635 (0.0538, 0.0732)	0.0635 (0.0538, 0.0732)	0.00251 (0.00125, 0.00377)	0.00425 (0.0023, 0.0062)	0.000529 (4.43×10 <sup>-5</sup> , 0.00101)	0.0188 (0.0138, 0.0238)	1.000	1.000	P(M D)	Marker frequency in people affected <sup>§</sup>
	0.892	0.892	0.439 (0.358, 0.520)	0.439 (0.358, 0.520)	0.536 (0.211, 0.877)	0.579 (0.291, 0.884)	0.91	0.701 (0.491, 0.926)	1.000	1.000	P(D M)	Penetrance <sup>§</sup>
	0.9996	0.9996	0.95	0.990	0.9996	0.9996	0.9996	0.9996	0.990	0.990	P(T M)	Test sensitivity
	0.9995	0.9995	0.98†	0.900	0.9995	0.9995	0.9995	0.9995	0.900	0.900	P(T' M')	Test specificity
	0.889	0.127	0.0198	0.00519	0.0194	0.0302	0.00683	0.109	0.908	0.00404	P(D T)	Disease risk after positive test
	0.0497	0.0000257	0.00489	0.00313	0.00333	0.00332	0.00333	0.00327	0.011	0.00000456	P(D T')	Disease risk after negative test
	17.9 (889,000 <sup>Ω</sup> )	4,961	4.06 (6.35 <sup>o</sup> )	1.66	5.84	9.09	2.05	33.3	82.7	887		Relative disease risk after positive rather than negative test